Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B-FAST: Blood-First Assay Screening Trial in Advanced NSCLC
NCT03178552Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Sep 2017
- Primary completion
- Jun 2027
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Allosteric Modulators
- Countries
- 27
01
Overview
Phase 3, randomised, open-label trial of alectinib, atezolizumab, entrectinib and divarasib in non-small cell lung cancer (NSCLC) (11 cohorts), sponsored by Roche. Primary endpoints: Objective Response Rate, Progression Free Survival and 2 more. Started Sep 2017; status: active, not recruiting.
02
Drugs
alectinibatezolizumabentrectinibdivarasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03178552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03178552.